Search company, investor...


About Solixia

Solixia is a biotechnology company dedicated to helping cancer patients through the use of nanoparticle technology.

Headquarters Location

3733 Spruce Street

Philadelphia, Pennsylvania, 19104,

United States

Missing: Solixia's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Solixia's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Solixia

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Solixia is included in 1 Expert Collection, including Cancer.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Solixia Frequently Asked Questions (FAQ)

  • Where is Solixia's headquarters?

    Solixia's headquarters is located at 3733 Spruce Street, Philadelphia.

  • Who are Solixia's competitors?

    Competitors of Solixia include Lipella Pharmaceuticals, Longevica, Array Biopharma, Biosceptre International, Sharklet Technologies and 12 more.

Compare Solixia to Competitors


Abraxis BioScience is a biotechnology company dedicated to delivering progressive therapeutics and core technologies that offer patients and medical professionals safer and more effective treatments for cancer and other critical illnesses. The Abraxis portfolio includes the protein-based nanoparticle chemotherapeutic compound (ABRAXANE) which is based on its tumor targeting system known as the nab' Technology platform.


Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo's development pipeline includes alfimeprase, a direct-acting fibrinolytic for the treatment of thrombotic- related disorders including acute ischemic stroke and catheter occlusion and preclinical candidates NU206 for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease and NU172, a direct thrombin inhibitor for use as a short-acting anticoagulant during medical or surgical procedures. In addition, Nuvelo expects to leverage its expertise in cancer antibody discovery to further expand its pipeline and create additional partnering and licensing opportunities.

Algae Biosciences

Algae Biosciences Corporation ("AlgaeBio") is a biotechnology company that aims to produce ultra-pure products from microalgae and macroalgae in a facility located near Holbrook, Arizona. The company has been producing microalgae on a small scale since October 2006. It aims to offer, per the company, the tools for harnessing the potential of the most prolific, abundant resource on the company's planet: the 200,000-plus known species of algae. Each species aims to offer downstream product potentials.


AgaPharm is developing a prescription eye drop for Diabetics. The drug aims to offer a simple, low-cost treatment that can deliver a safe and effective dose to the eye, preventing or slowing down the onset of diabetic blindness and cataract. The company's Research Partner is the Biotechnology Research Institute at the National Research Council of the Government of Canada.

Timi3 Systems

Timi3 Systems, Inc., a biotechnology company, develops a non-invasive transcutaneous ultrasound system for the treatment of patients experiencing an acute myocardial infarction or heart attack. The company specializes in the non-invasive delivery of thrombolytic drugs that hasten the dissolution of thrombus during a myocardial infarction. Timi3 Systems, Inc. was founded in 1999 and is based in Santa Clara, California.

Osprey Pharmaceuticals

Osprey Pharmaceuticals is a privately held biotechnology company focused on developing and commercializing a first-in-class family of therapeutic proteins (Leukocyte Population Modulators) capable of treating chronic diseases. Osprey's broad technology platform is based on the critical insight that many common diseases are propagated by overabundant and overactive leukocytes. The company's proprietary LPMs selectively and systematically destroy disease-related leukocytes by infiltrating the chemokine system that regulates the movement and activity of leukocytes.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.